Australia recorded its deadliest day of the coronavirus pandemic on Wednesday, while New Zealand reimposed restrictions as it investigates its first cases in more than three months.

(Reuters Breakingviews) - Pharmaceutical groups such as AstraZeneca and Pfizer may soon get regulators’ blessing for new coronavirus inoculations. A successful vaccine could ease a crisis that the Congressional Budget Office estimates will cost the United Sta…

Hello, Welcome to Dispensed, Business Insider's weekly healthcare newsletter. Andrew Dunn checking in for this week's round-up.  Are you new to the newsletter? You can sign up here.  Some highlights of the week: Pricing levels on coronavirus vaccines are comi…

(Reuters Breakingviews) - Corona Capital is a daily column updated throughout the day by Breakingviews columnists around the world with short, sharp pandemic-related insights.

Developing world stocks climbed on Tuesday, with rising bets of a dovish stance from the U.S. Federal Reserve to support the world's biggest economy, while South African gold miners slipped as prices of precious metal retreated from record highs.

Developing world stocks climbed on Tuesday, with rising bets of a dovish stance from the U.S. Federal Reserve to support the world's biggest economy, while South African gold miners slipped as prices of precious metal retreated from record highs.

European efforts to secure potential COVID-19 vaccines from Pfizer , Sanofi and Johnson & Johnson are mired in wrangles over price, payment method and potential liability costs, three EU officials told Reuters.

Hello, Welcome to Dispensed, Business Insider's weekly healthcare newsletter. See the rest of the story at Business InsiderNOW WATCH: Why American sunscreens may not be protecting you as much as European sunscreensSee Also:

Changes to executive stock-sale plans in May allowed hot biotech's top two leaders to cash out an extra $4 million in July.

German biotech company CureVac said Qatar Investment Authority (QIA) has taken an undisclosed stake in the firm as part of a $126 million financing round, the latest high-profile investor to come onboard ahead of a potential stock market listing.

Wall Street gained ground on Monday and surging technology shares pushed the Nasdaq to a record closing high, as promising trial results from potential COVID-19 vaccines helped investors look beyond spiraling new cases of the disease.

Hello, Welcome to Dispensed, Business Insider's weekly healthcare newsletter.  This week, amid rising coronavirus hospitalizations and political attacks on Dr. Anthony Fauci for his response to the pandemic, we covered new developments in the vaccine race, wh…

Most stocks and currencies in Latin America declined on Thursday, as souring relations between the United States and China and surging cases of the COVID-19 drove investors out of riskier assets. Hurting sentiment further was data which showed unexpected…

Most stocks and currencies in Latin America declined on Thursday, as souring relations between the United States and China and surging cases of the COVID-19 drove investors out of riskier assets. Hurting sentiment further was data which showed unexpected…

Welcome to Dispensed Daily, your daily dose of healthcare news from Business Insider's healthcare editor Lydia Ramsey Pflanzer. Subscribe here to get this newsletter in your inbox every weekday. Hello, Today in healthcare news: a look inside the secretive go…

World shares strode to four-month highs on Wednesday as hopes for a coronavirus vaccine offset rising U.S.-China tensions and also helped lift the euro and oil prices on improved sentiment.

(Reuters Breakingviews) - Corona Capital is a daily column updated throughout the day by Breakingviews columnists around the world with short, sharp pandemic-related insights.

Brazilian stocks hit a more than four-month high on Wednesday as signs of progress in developing a coronavirus vaccine invited more buying into risk-driven assets, even as COVID-19 cases piled. The Bovespa stock index rose about 1% to its highest level si…

(Reuters Breakingviews) - Corona Capital is a daily column updated throughout the day by Breakingviews columnists around the world with short, sharp pandemic-related insights.

RT @JohnWest_JAWS: Hmm.. Interesting that the decision to axe Valverna (at a £358m cost to taxpayer) and instead award the contract to Mod…

RT @JohnWest_JAWS: Hmm.. Interesting that the decision to axe Valverna (at a £358m cost to taxpayer) and instead award the contract to Mod…

If you’re trading this week, Read This! $MRNA MACD Histogram turned negative on June 22, 2023. #Moderna #stockmarket #stock https://t.co/aeDshANi6w https://t.co/jvd6z12yJJ

RT @JohnWest_JAWS: Hmm.. Interesting that the decision to axe Valverna (at a £358m cost to taxpayer) and instead award the contract to Mod…

RT @JohnWest_JAWS: Hmm.. Interesting that the decision to axe Valverna (at a £358m cost to taxpayer) and instead award the contract to Mod…

RT @JohnWest_JAWS: Hmm.. Interesting that the decision to axe Valverna (at a £358m cost to taxpayer) and instead award the contract to Mod…

RT @JohnWest_JAWS: Hmm.. Interesting that the decision to axe Valverna (at a £358m cost to taxpayer) and instead award the contract to Mod…

RT @JohnWest_JAWS: Hmm.. Interesting that the decision to axe Valverna (at a £358m cost to taxpayer) and instead award the contract to Mod…

RT @JohnWest_JAWS: Hmm.. Interesting that the decision to axe Valverna (at a £358m cost to taxpayer) and instead award the contract to Mod…

RT @JohnWest_JAWS: Hmm.. Interesting that the decision to axe Valverna (at a £358m cost to taxpayer) and instead award the contract to Mod…

RT @Geedub0411: @DiamondandSilk @rlockrocks A lotta corruption by pushing fake vaccines. Moderna had never, ever had a drug of any kind app…

All I can say is, don't buy stock in Moderna or Pfizer.

1. Its the flu 2. The vaccines were just a stock pump for Pfizer/JJ/AZ/Moderna investors (they actually got a bigger stock pump than bitcoin) https://t.co/drE0YqlSx0

RT @erica4ou: Moderna stock went from: $19 in January 2020 to $449 in September 2021 We always talk about Pfizer, but how many got mega…

RT @erica4ou: Moderna stock went from: $19 in January 2020 to $449 in September 2021 We always talk about Pfizer, but how many got mega…

RT @erica4ou: Moderna stock went from: $19 in January 2020 to $449 in September 2021 We always talk about Pfizer, but how many got mega…

3 Insiders at Moderna sold 110,000 shares last week for $14.0M $MRNA #Moderna #stockmarket #stock https://t.co/DovVK5kgLl

$MRNA was the market's top winner yesterday, jumping +3.61% #Moderna #stockmarket #stock https://t.co/fV7QHzksPR

All members of congress who made money on Pfizer and Moderna stock trades just prior to, and after THEY passed a ruling that PREVENTS ANYONE FROM SUING VACCINE COMPANIES EVEN IN THE EVENT OF INJURY; since they are and absolutely were EXPERIMENTAL and UNTESTED, should step down

$MRNA was this quarter's top loser, falling -18.32% #Moderna #stockmarket #stock https://t.co/IUoI6xRADU

4 Insiders at Moderna sold 97,855 shares last week for $12.2M $MRNA #Moderna #stockmarket #stock https://t.co/0Fv09tePO8

$MRNA - Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now? https://t.co/RYAIUZ3XPN

$MRNA - Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now? https://t.co/Z6VnDKppHr

$MRNA - Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now? https://t.co/16e4ONMg2e

$MRNA - Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now? https://t.co/EWFWUhGqFB

$MRNA - Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now? https://t.co/iwLbaZZxkX

$MRNA - Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now? https://t.co/ojb5Hc0c1G

$MRNA - Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now? https://t.co/H1MQV0Ww44

$MRNA - Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now? https://t.co/ATdY6gzOOi

$MRNA - Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now? https://t.co/ykwEsYHbde

$MRNA - Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now? https://t.co/wke44f7sGP

$MRNA - Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now? https://t.co/twEmifVmvu

$MRNA - Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now? https://t.co/NaCAGUwgZE

$MRNA - Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now? https://t.co/7oAl4ZJwON

$MRNA - Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now? https://t.co/m4VZLphQ5G

$MRNA - Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now? https://t.co/p0rMzsUoil

$MRNA - Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now? https://t.co/GJ4oVO5eMc

$MRNA - Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now? https://t.co/rLoWoz4UDQ

$MRNA - Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now? https://t.co/Ivyj7uMxnJ

Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now? | The Motley Fool https://t.co/WThnqlXuo8 ... to prove a cancer drug reduces patients' risk of disease recurrence. ... for its respiratory syncytial virus (RSV) vaccine later this year.